Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ARQL is in the long-term up 668% in 3 years.
Description: ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company?s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research
|Shares Outstanding||EPS||-0.36||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-4%||Sales Growth - Q/Q||-7.63%||P/E||-3.11|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-37.6%||ROE||-56.49%||ROI|
|Current Ratio||3.3||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.45|
|Gross Margin||Operating Margin||-191.68%||Net Profit Margin||-183.06%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||15.23 M||Cash From Operating Activities||-7.55 M||Gross Profit|
|Net Profit||-4.55 M||Operating Profit||-4.82 M||Total Assets||55.32 M||Total Current Assets||55.08 M|
|Total Current Liabilities||16.7 M||Total Debt||Total Liabilities||18.5 M||Total Revenue||2.79 M|
|High 52 week||7.03||Low 52 week||2.26||Last close||6.78||Last change||-3.56%|
|RSI||59.42||Average true range||0.4||Beta||1.25||Volume||304.8 K|
|Simple moving average 20 days||7.21%||Simple moving average 50 days||20.09%||Simple moving average 200 days||47.28%|
|Performance Week||5.61%||Performance Month||6.94%||Performance Quart||98.83%||Performance Half||84.74%|
|Performance Year||98.83%||Performance Year-to-date||144.77%||Volatility daily||3.84%||Volatility weekly||8.58%|
|Volatility monthly||17.58%||Volatility yearly||60.9%||Relative Volume||733.06%||Average Volume||1.57 M|
|New High||New Low|
2019-11-13 07:00:00 | ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019
2019-11-06 09:05:00 | ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
2019-10-30 08:25:12 | ArQule ARQL Reports Q3 Loss, Lags Revenue Estimates
2019-10-30 07:00:00 | ArQule Reports Third Quarter 2019 Financial Results
2019-10-28 17:15:45 | Hedge Funds Have Never Been This Bullish On ArQule, Inc. ARQL
2019-10-16 07:00:00 | ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019
2019-10-15 09:00:01 | All You Need to Know About ArQule ARQL Rating Upgrade to Buy
2019-10-08 08:47:12 | Health Check: How Prudently Does ArQule NASDAQ:ARQL Use Debt?
2019-10-03 10:56:02 | ArQule ARQL in Focus: Stock Moves 6.2% Higher
2019-09-26 07:00:00 | ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019
2019-08-30 14:39:07 | ArQule: Buy the Dip?
2019-08-28 07:00:00 | ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019
2019-08-09 11:07:05 | What Kind Of Shareholders Own ArQule, Inc. NASDAQ:ARQL?
2019-08-07 23:23:42 | Arqule Inc ARQL Q2 2019 Earnings Call Transcript
2019-08-07 19:17:08 | Edited Transcript of ARQL earnings conference call or presentation 7-Aug-19 1:00pm GMT
2019-08-07 08:45:12 | ArQule ARQL Reports Q2 Loss, Misses Revenue Estimates
2019-08-07 07:00:00 | ArQule Reports Second Quarter 2019 Financial Results
2019-08-06 14:18:30 | Arqule's Earnings Preview
2019-08-06 12:00:04 | ArQule ARQL to Post Q2 Earnings: What's in the Cards?
2019-08-05 07:00:00 | ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019
2019-07-31 10:36:02 | Analysts Estimate ArQule ARQL to Report a Decline in Earnings: What to Look Out for
2019-07-24 09:00:01 | What Makes ArQule ARQL a New Buy Stock
2019-07-24 07:00:00 | ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019
2019-07-12 07:15:00 | 5 Best Biotech Stocks of 2019 So Far
2019-07-08 13:58:00 | Here's Why ArQule Jumped 53.1% in June
2019-06-26 08:54:12 | Do Options Traders Know Something About ArQule ARQL Stock We Don't?
2019-06-25 15:16:00 | Here's the Surprising Reason ArQule Shares Rose as Much as 11% Today
2019-06-25 07:00:00 | ArQule Announces Pricing of $90 Million Public Offering of Common Stock
2019-06-24 16:37:00 | ArQule Announces Commencement of Proposed Public Offering of Common Stock
2019-06-24 13:27:28 | Did Hedge Funds Drop The Ball On ArQule, Inc. ARQL ?
2019-06-17 15:22:51 | Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal
2019-06-17 15:21:00 | ArQule Hits 12-Year High Following Favorable Midstage Study Results
2019-06-17 13:10:54 | 2 Rallying Pharma Stocks Roping In Option Bulls
2019-06-17 12:37:00 | Here's Why ArQule Is Soaring Again Today
2019-06-17 09:31:01 | Company News For Jun 17, 2019
2019-06-17 09:00:00 | ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib ARQ 092, in Patients with PIK3CA-related Overgrowth Spectrum PROS and Proteus syndrome PS in an Oral Presentation at the European Society of Human Genetics Conference
2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
2019-06-14 13:18:10 | ArQule News: ARQL Stock Skyrockets on Blood Cancer Study Results
2019-06-14 12:56:21 | A Look At Benzinga Pro's Most-Searched Tickers For June 14
2019-06-14 11:52:00 | Here's Why ArQule Shares Rose as Much as 44.7% Today